Post de Sensorion

🚀 Exciting Times in Biotech: Abselion Joins £1.1M Project for Next-Gen Viral Vector Production! 🧬 Abselion is teaming up with VVector Bio, Revvity, and the National Research Council (NRC) to revolutionize viral vector manufacturing, a key component in cell and gene therapy. Backed by a £1.1M grant from Innovate UK and NRC IRAP, the project aims to enhance the genetic functionality of the HEK-293 cell line. This collaboration is expected to overcome current hurdles like low yields and scalability, accelerating the development of life-changing therapies. 🌟 🔍 By leveraging genomics, transcriptomics, and process optimization analytics, this initiative is set to redefine biomanufacturing. As Abselion’s CEO Ruizhi Wang said, it’s an incredible opportunity to showcase the potential of next-gen therapeutics! 🙌 https://lnkd.in/daT5qPRd #Biotech #GeneTherapy #Innovation #Biomanufacturing #LifeSciences #CellTherapy #HealthcareTransformation

Les biomédicaments = un maillon essentiel pour notre santé ! RDV le 07/07 pour une journée dédiée #JNBB2024 🚀

Émulsion, encapsulation de composés de type API, peptide, virus, cellule, acide nucléique, ça vous dit quelque chose ? Microfluidique ça vous parle ? Nous avions rencontré le CEO de la belge Secoya Technologies il y a un peu moins de 3 ans lors de notre précédent Congrès Cell and Gene Therapies vol.4 au Brussels South Charleroi BioPark. Ce qu'il développait déjà à l'époque avec des sociétés du BioPark m'avait impressionnée. Il revient pour cette 5ème édition les 12 et 13 mars 2024, en tant que sponsor cette fois-ci, au même endroit, pour nous présenter sa dernière petite merveille d'innovation, l'Instadrop, la plateforme pour la production d’émulsions contrôlées… Facile d’utilisation, efficace et totalement adaptée aux développements en encapsulation ! Il sera d'ailleurs accompagné par son Tech Leader encapsulation avec lequel les participants pourront approfondir la connaissance de cette incroyable machine. En attendant, Secoya Technologies nous a confié un article afin d'en connaitre davantage sur l'Instadrop ainsi que sur la société. Je vous invite à le lire : https://lnkd.in/ef4g9B_v Mais le mieux, bien sûr, c'est de s'inscrire au Congrès européen Cell and Gene Therapies pour en discuter avec eux de vive voix ! Pour s'inscrire à l'événement connectez-vous sur notre site Buzz4bio Ce lundi J-1mois pour la tenue de l'événement ! Le compte-à-rebours commence. Les participants vont rece voir les méls d'information. J-3 semaines pour l'ouverture de la PF de RV d'Affaires ! Bertrand Loriers Dominique Demonte Murielle RATA #encapsulation #emulsion #biopharmaceutique #biotech #celltherapies #genetherapies #cellandgenetherapies #API #Peptide #virus #culturecellulaire #microfluidique

🚀 Exciting News Alert! 🚀 London-based investment firm Syncona is at it again, overseeing the creation of a groundbreaking entity called Spur Therapeutics! 🌟 With a 99% ownership stake, Syncona is paving the way for Spur to revolutionize gene therapy treatments for Gaucher disease and adrenomyeloneuropathy. 🧬 Under the leadership of Michael Parini, former CEO of Freeline, Spur is set to soar to new heights in the biotech world. 🚀 Keep an eye out for their AMN program's safety data, expected to drop in the first half of next year - it's going to be a game-changer! 💡 And that's not all - with a promising pipeline that includes a program for Parkinson's disease, Syncona's vision for Spur is nothing short of awe-inspiring. 🌠 Stay tuned for more updates on this dynamic collaboration! 🌟 #Biotech #Innovation #GeneTherapy #Syncona #SpurTherapeutics

Des questions sur l’exercice de comparabilité en cas de changements majeurs (changement de site ou optimisation de process) ? Venez en discuter avec nous le 21 Novembre à Lyon ! 🧬

In the fast-evolving world of cell and gene therapy (CGT), speed and precision are everything. However, with complex manufacturing processes and unpredictable (and often very high!) costs, bringing life-saving therapies from bench to bedside remains a monumental challenge. That’s why Taiwan Bio Therapeutics Inc. and Hyperius Biotech are joining forces to bring holistic support to CGT ventures and create a new paradigm in CGT development and manufacturing. At the core of this partnership lies an ambitious vision: to make CGT development more efficient, predictable, and accessible. By merging Hyperius’ venture creation and development expertise with Taiwan Bio’s industry-leading innovations in process and analytical development (PAD) technology, we’re set to redefine what’s possible in the CGT industry. With our combined strengths, this collaboration is about more than just overcoming manufacturing hurdles—it’s about reimagining the entire pathway to advanced therapies and building a sustainable, supportive ecosystem for CGT companies everywhere.

At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), our research focuses on the #SIRT6 gene which may hold the key to extending the #healthspan of humans and their canine companions. A mutation known as "#Centenarian SIRT6" could be crucial for developing new treatments. The following highlights underscore our unique position: ✅ immense global market with few competing treatments ✅ impressive, long life IP for both gene & gene delivery ✅ key clinical and regulatory milestones expected in next 18 months Learn more about #GENF's cutting edge work here: https://loom.ly/MeQymHs

Découvrez la newsletter du printemps sur les technologies avancées de Promega Corporation : thérapie génique, ARNm, tests de prolifération ou immunoassay,... De nombreuses thématiques sont abordées. Promega Switzerland Promega France

🧬 Vos produits influencent-ils l'expression génique ? That is the question ! Pour y répondre, contactez-nous et étudions l’impact de vos produits sur l’expression de gènes ! Par nos services de RT-qPCR, nous analysons la quantité de transcrits de gènes d’intérêt à partir d'échantillons très variés, et établissons ainsi des profils de comparaison d'effet de produits sur l'expression génique ! #qPCR #expressiongénique #transcription #transcrits #biologiemoléculaire ----------- 🧬 Do your products influence gene expression? That is the question! To find out, contact us, and let's study the impact of your products on gene expression! Through our RT-qPCR services, we analyze the quantity of gene transcripts of interest from various samples, allowing us to establish comparative profiles of product effects on gene expression! #qPCR #geneexpression #transcription #transcripts #molecularbiology

A roundtable not to be missed! Come hear panelist Farzin Farzaneh on Thurs, May 30, 9:15-10:15am at #ISCT2024 Session title: The 3rd Party Service Provider: Unavoidable Necessity or Powerful Partner? Room 205-207, Vancouver Convention Center East   Moderator: Massimo Dominici, MD University Hospital of Modena Reggio Emilia - Modena Policlinic, Italy Panelists:  Snehal Patel, Chief Technical Officer, Sana Biotechnology, Inc., USA Farzin Farzaneh, PhD, Chief Scientific Officer, ViroCell Biologics, UK Karen Walker, Chief Technical Officer, Kyverna Therapeutics, USA   Description: The cost to build the supporting infrastructure and hire the team you need to fully support the development, manufacturing and testing of CGT products is not easily absorbed by most biotech companies, and even some big pharma. One might also argue that it shouldn’t be borne by those companies, that the funding they receive should go towards what they do best; research, early development and discovery, advocacy and education, and clinical management. Many other companies, namely service providers, are funded explicitly to provide that infrastructure and support as efficiently and expertly as possible, so it's logical to argue we should leave that job to them. How do we best divide those responsibilities and conquer the challenges involved to bring therapeutics to market faster? See you there! Traci Kyes Makis Sigalas ISCT, International Society for Cell & Gene Therapy #viralvectors #cellandgenetherapy #genetherapy #celltherapy #clinicaltrials